Letter from the Editor


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 832.

Product Description

Already 2007 is shaping up to be an interesting time. A new Congress, shifting demographics, regulatory restrictions, and other factors are sure to keep industry leaders on their toes.
In early December, Pfizer’s two big announcements made headlines: first, a major reduction in its salesforce, then the discontinuation of clinical trials for one of its most promising new drugs.
Such events and others will define 2007…